Publications
Detailed Information
Cannabinoid-2 receptor agonist confers doxorubicin resistance in hepatocellular carcinoma cells by inducing p42/44 MAPK activation and NFkB-dependent IL-8 production : 간세포암 세포주에서 p42/44 MAPK 활성화와 NFkB 의존적 인터루킨 8 생성에 의한 카나비노이드 2 수용체 작용제 유발 독소루비신 내성
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 윤정환 | - |
dc.contributor.author | 장은선 | - |
dc.date.accessioned | 2019-07-09T17:44:02Z | - |
dc.date.available | 2019-07-09T17:44:02Z | - |
dc.date.issued | 2011-02 | - |
dc.identifier.other | 000000030455 | - |
dc.identifier.uri | https://hdl.handle.net/10371/158317 | - |
dc.identifier.uri | http://dcollection.snu.ac.kr:80/jsp/common/DcLoOrgPer.jsp?sItemId=000000030455 | ko_KR |
dc.description | 학위논문 (석사)-- 서울대학교 대학원 : 의학과 내과학전공, 2011.2. 윤정환. | - |
dc.format.extent | iii, 40 leaves | - |
dc.language.iso | eng | - |
dc.publisher | 서울대학교 대학원 | - |
dc.subject | 카나비노이드 2 수용체 | - |
dc.subject | 카나비노이드 | - |
dc.subject | 간세포암 | - |
dc.subject | 독소루비신 | - |
dc.subject | 약제내성 | - |
dc.subject | 인터루킨 8 | - |
dc.subject | Receptor | - |
dc.subject | Cannabinoid | - |
dc.subject | CB2 | - |
dc.subject | Cannabinoids | - |
dc.subject | Carcinoma | - |
dc.subject | Hepatocellular | - |
dc.subject | Doxorubicin | - |
dc.subject | Drug resistance | - |
dc.subject | Mitogen-Activated Protein Kinase | - |
dc.subject | NF-kappa B | - |
dc.subject | Interleukin-8 | - |
dc.title | Cannabinoid-2 receptor agonist confers doxorubicin resistance in hepatocellular carcinoma cells by inducing p42/44 MAPK activation and NFkB-dependent IL-8 production | - |
dc.title.alternative | 간세포암 세포주에서 p42/44 MAPK 활성화와 NFkB 의존적 인터루킨 8 생성에 의한 카나비노이드 2 수용체 작용제 유발 독소루비신 내성 | - |
dc.type | Thesis | - |
dc.type | Dissertation | - |
dc.description.degree | Master | - |
dc.contributor.affiliation | 의학과 내과학전공 | - |
dc.date.awarded | 2011-02 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.